Deucravacitinib治疗斑块状银屑病:POETYK PSO-1、PSO-2及长期扩展试验的4年安全性和有效性结果
该研究基于POETYK PSO-1、PSO-2及长期扩展试验,评估deucravacitinib治疗中重度斑块状银屑病长达4年的安全性和有效性。共1519例患者接受至少一剂deucravacitinib,累积暴露4392.8人年。结果显示安全性特征一致,疗效持久,持续治疗患者PASI 90和DLQI 0/1应答率从1年到4年维持良好。
要点
- Deucravacitinib治疗4年安全性特征一致,多数不良事件发生率随时间下降或持平。
- 持续治疗患者PASI 90应答率1年为45.6%,4年为47.5%,疗效持久。
- DLQI 0/1应答率1年为51.5%,4年为49.4%,患者报告结局维持良好。
核心结论
- Deucravacitinib在中重度斑块状银屑病患者中治疗4年显示出持续一致的安全性和持久疗效。
研究设计与样本
- 研究纳入III期POETYK PSO-1、PSO-2及长期扩展试验,PSO-1和PSO-2随机分配患者至口服安慰剂、deucravacitinib 6 mg每日一次或阿普米司特30 mg每日两次。
- 第52周时,患者进入长期扩展试验接受开放标签deucravacitinib 6 mg每日一次。
- 安全性分析纳入至少接受一剂deucravacitinib的患者共1519例,累积暴露4392.8人年。
- 疗效分析纳入从母试验第1天起持续接受deucravacitinib并进入长期扩展试验的患者共513例。
主要发现
- 严重不良事件(包括COVID-19)发生率从5.68/100人年降至5.01/100人年,死亡从0.20/100人年升至0.25/100人年。
- 因不良事件停药率从4.38/100人年降至2.20/100人年,带状疱疹从0.81/100人年降至0.55/100人年。
- 恶性肿瘤发生率从1.02/100人年降至0.89/100人年,主要心血管不良事件从0.30/100人年升至0.32/100人年,静脉血栓栓塞从0.20/100人年降至0.07/100人年。
- 持续治疗患者PASI 90应答率1年为45.6%(95% CI 41.3%-50.0%),4年为47.5%(95% CI 42.6%-52.4%);DLQI 0/1应答率1年为51.5%(95% CI 47.1%-55.9%),4年为49.4%(95% CI 44.4%-54.4%)。
临床怎么用
- Deucravacitinib可作为中重度斑块状银屑病系统治疗的长期选择,4年数据支持其持续使用。
- 治疗期间需关注不良事件、严重不良事件、带状疱疹、恶性肿瘤、主要心血管不良事件和静脉血栓栓塞等安全性指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. OBJECTIVES: To evaluate the safety and efficacy of deucravacitinib through 4 years in the Phase 3 POETYK PSO-1, PSO-2 and long-term extension (LTE) trials in psoriasis. METHODS: PSO-1 and PSO-2 (parent trials) randomized patients 1:2:1 to oral placebo, deucravacitinib 6 mg once daily (QD) or apremilast 30 mg twice daily. At 52 weeks, patients enrolled in the LTE trial received open-label deucravacitinib 6 mg QD. Safety was evaluated in patients who received ≥1 dose of deucravacitinib at any time. Clinical and patient-reported outcomes (PASI, PGA and DLQI) were analysed in patients who received continuous deucravacitinib from Day 1 of the parent trials and enrolled in the LTE trial. RESULTS: In total, 1519 patients received ≥1 dose of deucravacitinib, with cumulative exposure of 4392.8 person-years (PY) through the data cut-off of 1 November 2023. Exposure-adjusted incidence rates (EAIRs)/100 PY of noted safety measures were comparable or decreased from the 1-year to 4-year cumulative period, respectively, for adverse events (AEs) (229.23, 131.68), serious AEs (including COVID-19) (5.68, 5.01), deaths (0.20, 0.25), discontinuation due to AEs (4.38, 2.20), herpes zoster (0.81, 0.55), malignancies (1.02, 0.89), major adverse cardiovascular events (0.30, 0.32) and venous thromboembolism (0.20, 0.07). In patients who received continuous deucravacitinib (n = 513), clinical and patient-reported outcome rates were well maintained from 1 year through 4 years (e.g. PASI 90, 1 year, 45.6% [95% CI, 41.3%-50.0%], 4 years, 47.5% [42.6%-52.4%]; DLQI 0/1, 1 year, 51.5% [47.1%-55.9%], 4 years, 49.4% [44.4%-54.4%]). CONCLUSIONS: Deucravacitinib demonstrated a consistent safety profile and durable efficacy through 4 years of treatment in patients with moderate to severe plaque psoriasis.
引用
- Armstrong AW, Lebwohl M, Warren RB, et al. Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. J Eur Acad Dermatol Venereol. 2025. PMID: 40045918. doi:10.1111/jdv.20553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。